News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News Amgen's BiTE for lung cancer backed for EU approval Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
News 11 blockbuster drugs to look out for in 2025 Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
News Amgen adds BiTE to its cancer range as FDA clears Imdelltra Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
